Abstract: In order to remove olefinic impurities present in a hydrofluorocarbon such as pentafluoroethane (R-125), the impure hydrofluorocarbon is treated with oxygen in the absence of catalyst or of active charcoal.The process is well suited to the purification of fluoroethanes and, more particularly, to that of pentafluoroethane.

Abstract: This invention relates to an ethylene oxide catalyst which contains silver and one or more alkali metal promoters supported on a carrier prepared by a process comprising the use of ceramic particle components with particle sizes chosen to ensure that a desired degree of porosity is obtained without the use of organic burnout materials.

Abstract: The invention relates to borneol derivatives of general formula I ##STR1## in which R.sup.1 means C(O)--CH(OR.sup.6)--CH(NHR.sup.7)--R.sup.8,R.sup.2 means hydrogen, --OH, C.sub.1 -C.sub.10 alkyl, C.sub.1 -C.sub.10 alkoxy, --OC(O)R.sup.9a, --OSO.sub.2 R.sup.9a, --OP(O)(OH).sub.2, NHR.sup.9a, NR.sup.9a R.sup.9b,R.sup.3 means hydrogen, --OH, C.sub.1 -C.sub.10 alkoxy, --OC(O)R.sup.9b, --OSO.sub.2 R.sup.9b, --OP(O)(OH).sub.2, orR.sup.2, R.sup.3 together mean an oxygen atom,R.sup.4 means hydrogen, C.sub.1 -C.sub.10 alkyl, --(CH.sub.2).sub.n --OR.sup.11a,R.sup.5 means hydrogen, C.sub.1 -C.sub.10 alkyl, --(CH.sub.2).sub.p --OR.sup.11b, orR.sup.4, R.sup.5 together mean an oxygen atom, a=CHR.sup.10 group,n means 0 to 8,p means 1 to 8,R.sup.7 means --C(O)R.sup.12, --SO.sub.2 R.sup.12, --C(O)OR.sup.12, --C(O)NHR.sup.9d, --C(O)NR.sup.9d R.sup.9e, ##STR2## R.sup.8 means aryl, R.sup.9a-e, R.sup.12 are the same or different and mean C.sub.1 -C.sub.10 alkyl, C.sub.4 -C.sub.8 cycloalkyl, aryl, C.sub.7 -C.sub.16 aralkyl,R.sup.

Abstract: A process for preparing a compound having the formula: ##STR1## wherein R is selected from the group consisting of C.sub.3 -C.sub.6 -cycloalkyl, C.sub.3 -C.sub.6 -cycloalkylmethyl, C.sub.1 -C.sub.6 -alkyl, allyl and 2-methoxyethyl, by reacting: ##STR2## under defined conditions with subsequent stepwise reactions of the respective intermediate compounds with a malonic acid diester, POCl.sub.3, and by heating the final intermediate in a high boiling solvent.

Abstract: Compounds of Formula I ##STR1## in which the variables are defined herein, processes for the production thereof as well as pharmaceutical agents containing these compounds for the treatment of diseases which are the result of thromboembolytic events.

Abstract: Cisapride, i.e. cis-4-amino-5-chloro-N-?1-?3-(4 fluoro-phenoxy)propyl!-3-methoxy-4-piperidinyl!-2-methoxy-benzamide, and similar benzamide derivatives, are prepared from novel 1-aryloxyalkyl- or 1-aralkyl-3-arylcarbonyloxy-4-oxo-piperidines, by nuclear substituent re arrangement involving acyl transfer under animal forming conditions, to give the corresponding 1-aryloxyalkyl- or 1-aralkyl-3-hydroxy-4-lower alkoxy-4-arylamido piperidine. This in turn is readily converted to the corresponding 3-oxo-4-arylamido-piperidine by reaction with strong organic acid, which can then be reduced, deprotected and 3-methylated to give the final compound, e.g. cisapride.

Abstract: There is provided an alcohol composition obtained by dimerizing an olefin feed comprising C.sub.6 -C.sub.10 linear olefins to obtain C.sub.12 -C.sub.20 olefins, followed by conversion to alcohols, such as by hydroformylation. The composition has an average number of branches ranging from 0.9 to 2.0 per molecule. The linear olefin feed preferably comprises at least 85% of C.sub.6 -C.sub.8 -olefins. The primary alcohol compositions are then converted to anionic or nonionic surfactants, preferably sulfated or oxyalkylated or both. The sulfated compositions are biodegradable and possess good cold water detergency. The process for making the dimerized primary alcohol comprises dimerizing, in the presence of a homogeneous dimerization catalyst under dimerization conditions, an olefin feed comprising C.sub.6 -C.sub.10 olefins and preferably at least 85 weight % of linear olefins based on the weight of the olefin feed, to obtain a C.sub.12 -C.sub.20 ; optionally double bond isomerizing said C.sub.12 -C.sub.

Abstract: A process is described for the preparation of (+)-2-(3,4-dichlorophenyl)-4-hydroxybutylamine (I) by reaction of 3,4-dichlorophenylacetic acid (II) with an alkali metal halogenoacetate, treatment of the 3-cyano-3-(3,4-dichlorophenyl)propionic acid (III) with D-(-)-N-methylglucamine, with second-order asymmetric conversion, hydrolysis of the D-(-)-N-methylglucamine salt of (-)-3-cyano-3-(3,4-dichlorophenyl,)propionic acid and enantioconservative reduction of the resulting levorotatory cyanoacid with a borane.

Abstract: This invention relates to lactam and thiolactam derivatives having useful anticonvulsant and anxiolytic activity, pharmaceutical compositions containing these compounds and therapeutic applications using such compositions.

Abstract: The present invention is concerned with diaryl compounds of formula (l) and their use in medical therapy, particularly in the prophylaxis or treatment of a clinical condition for which an ACAT inhibitor is indicated, such as hyperlipidaema or atherosclerosis. The invention also relates to pharmaceutical compositions and processes for the preparation of compounds according to the invention.

Abstract: A process for producing a fluorinated olefin having the formula:CH.sub.3-a F.sub.a CH.dbd.CHClwhere a=1,2 or 3, said process comprising catalytically reacting a chlorinated organic compound with a fluorination agent under conditions sufficient to form said hydrofluorocarbon compound, said chlorinated organic compound having the formula:CH.sub.b Cl.sub.c F.sub.d CH.sub.e CHCl.sub.ewhere b=0, 1 or 2; c=0, 1, 2, or 3; d=0, 1, 2 or 3; and e=1 or 2 with the provisos that b+c+d=3, c+e>1 and b+e<4.

Abstract: A process for the continuous preparation of 4-amino-2,2,6,6-tetramethylpiperidine (TAD), comprising: passing triacetoneamine, ammonia and hydrogen over a catalyst of at least two layers in a reactor, wherein at least one catalyst layer comprises at least one element of the 4th, 5th, or 6th row of the 8th transition group of the Periodic Table or combinations of these metal elements on a suitable support, where the catalyst content with respect to each individual catalytically active element changes independently from the reactor inlet to the reactor outlet.

Abstract: A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sub.1 represents ##STR2## in which r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;R.sub.2 is a group OR.sub.4, where R.sub.4 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl or a group OCOR.sub.5 where R.sub.5 is hydrogen or R.sub.4 ; andR.sub.3 is CN;said process comprising reacting a compound of formula (II): ##STR3## wherein R.sub.1 ' is R.sub.1 or a group convertible thereto, and R.sub.3 ' is an electron withdrawing group, with a source of nitrous acid, and thereafter converting the resulting .dbd.NOH group to .dbd.NR.sub.2 wherein R.sub.2 is as defined in formula (I), converting R.sub.1 ' and R.sub.3 ' when other than R.sub.1 and R.sub.3 to R.sub.1 and R.sub.3, and thereafter optionally forming a pharmaceutically acceptable salt.

Abstract: The new compounds of formulaA--O--CO--Z (I)(wherein A and Z are defined as explained in the specification) can be prepared by conventional methods; they are suitable as active substances for pharmaceutical compositions.

Abstract: A process for the preparation of 1,2-butylene oxide by the catalytic hydrogenation of vinyl oxirane, in which use is made of a palladium catalyst on a support of barium sulfate, zirconium oxide or titanium dioxide or a rhenium-containing supported palladium catalyst.

Abstract: A propylene epoxidation process wherein a supported silver catalyst is utilized may be operated at high efficiency even in the absence of any organic chloride in the feedstream, provided the catalyst is first contacted at an elevated temperature with a treatment stream comprised of an organic chloride and molecular oxygen.

Abstract: An antiproliferative and antiviral preparation of a metal ion chelating agent such as picolinic acid or derivatives thereof. The chelating agent is provided in an ointment base or in solution for topical or intravaginal use. The topical preparations have antiviral and antiproliferative effects and are used in the treatment of warts, psoriasis, skin cancers and other proliferative diseases and in the prevention of sexually transmitted diseases such as genital warts, herpes and AIDS.

Abstract: The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure: ##STR1## wherein Y is --(CH.sub.2).sub.n --, where n is 1, 2, 3, 4 or 5; --(CH.sub.2).sub.h --O--(CH.sub.2).sub.k --, where h and k are independently the same or different and are 2, 3 or 4; --(CH.sub.2).sub.h --CH.dbd.CH--(CH.sub.2).sub.k --; or --(CH.sub.2).sub.h --C.tbd.C--(CH.sub.2).sub.k --, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is O, NH, or CH.sub.2 ; wherein R.sup.1 is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R.sup.2 and R.sup.4 are independently the same or different and are H, or a linear or branched chain alkyl group; wherein R.sup.3 is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R.sup.5 and R.sup.6 are independently the same or different and are H, OH, Cl, Br, F, NO.sub.2, CN, CF.

Abstract: A TPN solution to be prepared before using which comprises two separate infusions of an amino acid-infusion and a saccharide-infusion wherein both of said infusions contain no sulfite ion, either one of said infusions contains a water-soluble vitamin B, a pH of the infusion containing a water-soluble vitamin B is acidic and a pH of the TPN solution prepared by mixing both infusions is neutral. According to the TPN solution of the present invention, a water-soluble vitamin B can be stably preserved in a TPN solution for a long term though it has been recognized that the water-soluble vitamin B could not be contained in a TPN solution. The present invention enables to practically use a TPN solution previously containing a water-soluble vitamin B.

Abstract: The present invention relates to the synthesis of optionally alkoxylated polyorganosiloxane (POS) resins by non-hydrolytic condensation. The object is to provide a process which offers the possibility of controlling the crosslinking. This object, inter alia, is achieved by the process according to the invention, which makes provision for carrying out a non-hydrolytic condensation reaction between alkoxysilyl units (Mo1) and halogenosilyl units (Mo2), both of which are carried by identical or different silanes, in the presence of a catalyst of the Lewis acid type, said condensation reaction generating essentially .tbd.Si--O--Si.tbd. linkages and coproducts XR (X=halogen).